Search

Your search keyword '"Auperin A"' showing total 1,136 results
Start Over Author "Auperin A"
1,136 results on '"Auperin A"'

1. Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with FAB/LMB-based chemotherapy regimen with rituximab

Author

Marie Emilie Dourthe, Anne Auperin, Charlotte Rigaud, Melissa Barbati, Jacinthe Bonneau, Nimrod Buchbinder, Marie-Laure Couec, Peggy Dartigues, Stéphane Ducassou, Nathalie Garnier, Stéphanie Haouy, Bénédicte Jonca, Anne Jourdain, Amaury Leruste, Thierry Molina, Françoise Montravers, Marlène Pasquet, Aurélie Phulpin, Maryline Poirée, Mathieu Simonin, Alexandra Spiegel, Arnauld Verschuur, Thierry Leblanc, Judith Landman-Parker, Catherine Patte, and Véronique Minard-Colin

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Not available.

Published
2024
Full Text
View/download PDF

3. Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial

Author

Guigay, Joël, Le Caer, Hervé, Ferrand, François-Régis, Geoffrois, Lionel, Saada-Bouzid, Esma, Fayette, Jérôme, Sire, Christian, Cupissol, Didier, Blot, Emmanuel, Guillet, Pierre, Pavillet, Julien, Bozec, Laurence, Capitain, Olivier, Rolland, Frédéric, Debourdeau, Philippe, Pointreau, Yoann, Falandry, Claire, Lopez, Stéphane, Coutte, Alexandre, Chatellier, Thierry, Dalloz, Pierre, Ortholan, Cécile, Michel, Cécile, Lacas, Benjamin, Cheurfa, Nadir, Schwob, Dominique, Bourhis, Jean, Mertens, Cécile, and Aupérin, Anne

Published
2024
Full Text
View/download PDF

4. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Author

Aupérin, Anne, Blanchard, Pierre, Benhamou, Ellen, Bourhis, Jean, Carmel, Alexandra, Chakrabandhu, Somvilai, Chan, Anthony TC, Chen, Lei, Chen, Ming-Yuan, Chen, Qiu-Yan, Chen, Yong, Chappell, Richard J, Choi, Horace, Chua, Daniel TT, Chua, Melvien Lee Kiang, Fountzilas, George, Higgins, Julian, Hong, Ming Huang, Hong, Ruey-Long, Huang, Pei-Yu, Hui, Edwin Pun, Hsiao, Chin-Fu, Kam, Michael, Koliou, Georgia Angeliki, Kwong, Dora L W, Lacas, Benjamin, Lai, Shu-Chuan, Lam, Ka On, LeBlanc, Michael L, Lee, Anne WM, Lee, Ho Fun Victor, Li, Wen Fei, Lim, Yoke, Ma, Brigette, Ma, Jun, Mai, Hai-Qiang, Mo, Frankie, Moon, James, Ng, Wai Tong, Ngan, Roger, Ollivier, Camille, O'Sullivan, Brian, Petit, Claire, Pignon, Jean-Pierre, Poh, Sharon X, Rücker, Gerta, Sham, Jonathan, Soong, Yoke Lim, Sun, Ying, Tan, Terence, Tang, Lin-Quan, Tung, Yuk, Wee, Joseph, Wu, Xuang, Xu, Tingting, Zhang, Li, Zhang, Yuan, Zhu, Guopei, Lee, Anne, Chan, Anthony T C, Li, Wen-Fei, Ngan, Roger K C, Hui, Edwin P, and Auperin, Anne

Published
2023
Full Text
View/download PDF

5. Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial

Author

Guigay, Joël, Ortholan, Cécile, Vansteene, Damien, Cupissol, Didier, Even, Caroline, Kaminsky, Marie-Christine, Sire, Christian, Blot, Emmanuel, Debourdeau, Philippe, Bozec, Laurence, Saada-Bouzid, Esma, Fayette, Jérôme, Dalloz, Pierre, Pointreau, Yoann, Caer, Hervé Le, Falandry, Claire, Digue, Laurence, Braccini, Antoine, Lopez, Stéphane, Guillet, Pierre, Michel, Cécile, Cheurfa, Nadir, Schwob, Dominique, Bourhis, Jean, Mertens, Cécile, and Aupérin, Anne

Published
2024
Full Text
View/download PDF

7. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial

Author

Alexander, Sarah, Aupérin, Anne, Bomken, Simon, Csóka, Monika, Kazanowska, Bernarda, Chiang, Alan K, Andres, Mara, Uyttebroeck, Anne, Burke, G A Amos, Zsiros, József, Pillon, Marta, Bollard, Catherine M, Mussolin, Lara, Verdu-Amoros, Jaime, Neven, Bénédicte, Barkauskas, Donald A, Wheatley, Keith, Patte, Catherine, Gross, Thomas G, and Minard-Colin, Véronique

Published
2023
Full Text
View/download PDF

8. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

Author

Beishuizen, Auke, Mellgren, Karin, Andrés, Mara, Auperin, Anne, Bacon, Chris M, Bomken, Simon, Burke, G A Amos, Burkhardt, Birgit, Brugieres, Laurence, Chiang, Alan K S, Damm-Welk, Christine, d'Amore, Emanuele, Horibe, Keizo, Kabickova, Edita, Khanam, Tasneem, Kontny, Udo, Klapper, Wolfram, Lamant, Laurence, Le Deley, Marie-Cecile, Loeffen, Jan, Macintyre, Elizabeth, Mann, Georg, Meyer-Wentrup, Friederike, Michgehl, Ulf, Minard-Colin, Veronique, Mussolin, Lara, Oschlies, Ilske, Patte, Catherine, Pillon, Marta, Reiter, Alfred, Rigaud, Charlotte, Ronceray, Leila, Salaverria, Itziar, Simonitsch-Klupp, Ingrid, Uyttebroeck, Anne, Verdu-Amoros, Jaime, Williams, Denise, Woessmann, Wilhelm, Wotherspoon, Andrew, Wrobel, Grazyna, Zimmermann, Martin, Attarbaschi, Andishe, and Turner, Suzanne D

Published
2023
Full Text
View/download PDF

9. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Adelstein, D.J., Agarwal, J., Alfonsi, M., Argiris, A., Aupérin, A., Bacigalupo, A., Bar-Ad, V., Bartelink, H., Beadle, B., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Bratland, Å., Brizel, D., Budach, V., Budach, W., Burtness, B., Calais, G., Campbell, B., Caudell, J., Chabaud, S., Chamorey, E., Chaukar, D., Cheugoua-Zanetsie, M., Cho, K.H., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Dominello, M.M, Driessen, C.M.L., Fallai, C., Forastiere, A.A., Fortpied, C., Fountzilas, G., Garaud, P., Garden, A.S., Gery, B., Ghadjar, P., Ghi, M.G., Ghosh Laskar, S., Graff-Cailleaud, P., Grau, C., Gregoire, V., Hackshaw, A., Haddad, E, Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Jeremic, B., Johansen, J., Jones, C., Julieron, M., Kristensen, C.A., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Lartigau, E., Licitra, L., Le, Q.T., Lee, J.W., Lee, P., Lewin, F., Li, Y., Lopes, A., Lotayef, M., Maciejewski, B., Mazeron, J.J., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Moyal, E., Nankivell, M., Nilsson, P., Olmi, P., Orecchia, R., O'Sullivan, B., Overgaard, J., Parmar, M.K.B., Petit, C., Pignon, J.P., Pointreau, Y., Posner, M.R., Poulsen, M.G., Quon, H., Racadot, S., Rosenthal, D.I., Rovea, P., Ruo Redda, M.G., Sanguineti, G., Shenouda, G., Simes, J., Sharma, A., Simon, C., Sire, C., Skladowski, K., Spencer, S., Staar, S., Strojan, P., Stromberger, C., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Tobias, J.S., Torres-Saavedra, P., Torri, V., Tripcony, L., Trotti, A., Tseroni, V., van Herpen, C., van Tinteren, H., Vermorken, J., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Widder, J., Wolf, G.T., Wong, S.J., Wu, J.S., Yamazaki, H., Zaktonik, B., Zackrisson, B., Zhong, L.P., Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K B, Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R, Vokes, Everett E, Cruz Hernandez, Juan J, Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, and Blanchard, Pierre

Published
2021
Full Text
View/download PDF

11. Socioeconomic impact of the COVID-19 crisis and early perceptions of COVID-19 vaccines among immigrant and nonimmigrant people living with HIV followed up in public hospitals in Seine-Saint-Denis, France.

Author

Pauline Penot, Julie Chateauneuf, Isabelle Auperin, Hugues Cordel, Valerie-Anne Letembet, Julie Bottero, and Johann Cailhol

Subjects
Medicine, Science
Abstract

The burden of the first year of the coronavirus disease 2019 (COVID-19) pandemic was greater for vulnerable populations, such as immigrants, people living in disadvantaged urban areas, and people with chronic illnesses whose usual follow-up may have been disrupted. Immigrants receiving care for HIV in Seine-Saint-Denis' hospitals have a combination of such vulnerabilities, while nonimmigrant people living with HIV (PLWHIV) have more heterogeneous vulnerability profiles. The ICOVIH study aimed to compare the socioeconomic effects of the COVID-19 crisis as well as attitudes toward COVID-19 vaccination among immigrant and nonimmigrant PLWHIV. A questionnaire assessed vulnerabilities prior to the COVID-19 epidemic and the impact of the early epidemic on administrative, residential, professional, and financial fields. We surveyed 296 adults living with HIV at four hospitals in Seine-Saint-Denis, the poorest metropolitan French department, between January and May 2021. Administrative barriers affected 9% of French-born versus 26.3% of immigrant participants. Immigrants experienced financial insecurity and hunger more often than nonimmigrant participants (21.8% versus 7.1% and 6.6% versus 3%, respectively). Spontaneous acceptance of vaccination was higher among nonimmigrant than among immigrant participants (56.7% versus 32.1%), while immigrants were more likely to wait for their doctor's recommendation or for their doctor to convince them than their French-born counterparts (34.2% versus 19.6%). The trust-based doctor‒patient relationship established through HIV follow-up appeared to be a determining factor in the high acceptance of the COVID-19 vaccine among immigrant participants.

Published
2023
Full Text
View/download PDF

12. Tumors: Oto-Rhino-Laryngology

Author

Guigay, Joël, Ortholan, C., Auperin, A., Le Caer, H., Michel, C., Mertens, C., Hofman, Paul, Section editor, Boulahssass, Rabia, Section editor, Gu, Danan, editor, and Dupre, Matthew E., editor

Published
2021
Full Text
View/download PDF

13. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients

Author

Aupérin, Anne, Blanchard, Pierre, Benhamou, Ellen, Bourhis, Jean, Carmel, Alexandra, Chakrabandhu, Somvilai, TC Chan, Anthony, Chen, Lei, Chen, Ming-Yuan, Chen, Qiu-Yan, Chen, Yong, Chappell, Richard J, Choi, Horace, TT Chua, Daniel, Lee Kiang Chua, Melvin, Fountzilas, George, Higgins, Julian, Hong, Ming-Huang, Hong, Ruey-Long, Huang, Pei-Yu, Pun Hui, Edwin, Hsiao, C.F., Kam, Michael, Angeliki Koliou, Georgia, LW Kwong, Dora, Lacas, Benjamin, Lai, Shu-Chuan, On Lam, Ka, LeBlanc, Michael L, WM Lee, Anne, Fun Victor Lee, Ho, Fei Li, Wen, Ma, Brigette, Ma, Jun, Mai, Hai-Qiang, Mo, Frankie, Moon, James, Tong Ng, Wai, Ngan, Roger, Ollivier, Camille, O'Sullivan, Brian, Petit, Claire, Pierre Pignon, Jean, Poh, Sharon X., Rücker, Gerta, Sham, Jonathan, Lim Soong, Yoke, Sun, Ying, Tan, Terence, Tang, Lin-Quan, Tung, Yuk, Wee, Joseph, Wu, Xuang, Xu, Tingting, Zhang, Li, Zhang, Yuan, Zhu, Guopei, Lee, Anne W.M., Wai Tong, Ng, Chan, Anthony T.C., Hong, Ruey Long, Li, Wen-Fei, Kwong, Dora L.W., Poh, Sharon S.X., and Pignon, Jean-Pierre

Published
2022
Full Text
View/download PDF

15. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

BABA-HAMED, Nabil, BABIN, Emmanuel, BERA, Guillaume, BETRIAN-LAGARDE, Sarah, BLOT, Emmanuel, BOMPAS, Emmanuelle, BOREL, Christian, BOUCHEKOUA, Mohamed, BOZEC LE MOAL, Laurence, BRUYAS, Amandine, CALAIS, Gilles, CARPIUC, Ioana, CHAPET, Sophie, CHATELLIER, Thierry, CHAUFFERT, Bruno, CHELI, Sandrine, CLATOT, Florian, COJOCARASU, Oana, CORNELLY, Alexandre, COUTTE, Alexandre, DALLOZ, Pierre, DARLOY, Franck, DELHOMMEAU, Melissa, DE RAUCOURT, Dominique, DEBELLEIX, Christophe, DEBOURDEAU, Philippe, DILLIES-LEGRAIN, Anne Françoise, DO, Pascal, DUBOS-ARVIS, Catherine, DUCOULOMBIER, Agnès, EL KOURI, Claude, FALKOWSKI, Sabrina, FERRAND, François-Regis, GATINEAU, Michel, GERVAIS, Radj, GRAS, Louis, GUILLET, Pierre, HASBINI, Ali, HENAULT, Stéphane, HERRERA GOMEZ, Ruth Gabriela, HUGUET, Florence, KAMINSKY, Marie Christine, LAGRANGE, Aurélie, LAVAU-DENES, Sandrine, LE CAER, Hervé, LE FOLL, Christine, LEFEBVRE, Gautier, LINOT, Benjamin, LOPEZ, Qian, LORTHOLARY, Alain, MATIAS, Margarida, MAYACHE-BADIS, Lamia, MINNE, Floriane, MOLLON, Delphine, NEIDHARDT, Eve Marie, PAVILLET, Julien, PEYRADE, Frédéric, POINTREAU, Yohann, RAMEE, Jean-François, RAUCHE, Camille, RICHARD, Sandrine, RIZZO, Claudia, ROLLAND, Frédéric, SCHLURMANN, Friderike, STEFANI, Laetitia, TASSY, Louis, TAZI, Youssef, THERY, Jean-Christophe, TORTI EL ZEIN, Florida, TOULLEC, Clémence, TOURANI, Jean-Marc, TOUSSAINT, Philippe, VANBOCKSTAEL, Julie, VAULEON, Elodie, VIRET, Frédéric, WALER, Sabine, ATZPODIEN, Jens, BEHRENS, Caecilia, BUSCH, Chia Jung, DIETZ, Andreas, FELDMANN, Georg, FIETKAU, Rainer, GRANIZKA, Thordis, GREWE, Jürgen, GUNTINAS-LICHINUS, Orlando, HADLER-MIKESCH, Kristina, HAHN, Dennis, INHESTERN, Johanna, KELLNER, Karolin, KLINGHAMMER, Konrad, KRONENBERGER, Roland, LUEDTKE-HECKENKAMP, Kerstin, OCHSENREITHER, Sebastian, OTREMBA, Burkhard, PEUKER, Caroline Anna, PIRLICH, Markus, ROTHMANN, Frank, TOMETTEN, Mareike, WOHLFARTH, Sabine, ZEBRALLA, Veit, ZIPFEL, Matthias, ADANSA KLEIN, Juan Carlos, ARRAZUBI, Virginia, CABALLERO DAROQUI, Javier, CASTELO, Beatriz, CIRAUQUI CIRAUQUI, Beatriz, CRUZ HERNANDEZ, Juan Jesus, GALLEGO, Oscar, IGLESIAS DOCAMPO, Lara Carmen, LOPEZ POUSA, Antonio, MARTINEZ DEL PRADO, Maria, MARTINEZ-TRUFERO, Javier, PASTOR BORGONON, Miguel, PEREZ RUIZ, Elisabeth, QUIROGA GARCIA, Vanesa, RUBIO CASADEVALL, Jordi, VAZQUEZ FERNANDEZ, Silvia, Guigay, Joël, Aupérin, Anne, Fayette, Jérôme, Saada-Bouzid, Esma, Lafond, Cédrik, Taberna, Miren, Geoffrois, Lionnel, Martin, Laurent, Capitain, Olivier, Cupissol, Didier, Castanie, Hélène, Vansteene, Damien, Schafhausen, Philippe, Johnson, Alison, Even, Caroline, Sire, Christian, Duplomb, Sophie, Evrard, Camille, Delord, Jean-Pierre, Laguerre, Brigitte, Zanetta, Sylvie, Chevassus-Clément, Cécile, Fraslin, Aldéric, Louat, Fanny, Sinigaglia, Laura, Keilholz, Ulrich, Bourhis, Jean, and Mesia, Ricard

Published
2021
Full Text
View/download PDF

17. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study

Author

Marie Emilie Dourthe, Aurélie Phulpin, Anne Auperin, Jacques Bosq, Marie-Laure Couec, Peggy Dartigues, Stéphane Ducassou, Nathalie Garnier, Stéphanie Haouy, Thierry Leblanc, Amaury Leruste, Catherine Paillard, Charlotte Rigaud, Mathieu Simonin, Catherine Patte, and Véronique Minard-Colin

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Primary mediastinal large B-cell lymphoma (PMLBL) is a rare entity predominantly affecting adolescents and young adults. Recently, an international phase II trial in pediatric patients using dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) failed to reproduce excellent survival reported in some adult studies. The optimal therapy regimen needs to be determined in this disease. The French prospective LMB2001 trial included all patients ≤18 years with mature B-cell lymphoma treated in French centers. For patients with PMLBL, treatment included four to eight courses of Lymphomes Malins B (LMB)-based chemotherapy without radiotherapy. From 2008, rituximab was added before each chemotherapy course. From 09/2001 to 03/2012, 42 patients with PMLBL were registered. The median age was 15 years (range, 8-18). Twenty-one patients were treated with chemotherapy plus rituximab. The median follow-up was 7.1 years (interquartile range, 5.8-11.1). Five-year event-free and overall survival were 88.1% (95% confidence interval (CI): 75.0-94.8) and 95.2% (95% CI: 84.0-98.7) for the whole population. The 5-year EFS was 81.0% (95% CI: 60.0-92.3) and 95.2% (95% CI: 77.3-99.2) (hazard ratio =0.24; 95% CI: 0.03- 2.2) and 5-year overall survival was 90.5% (95% CI: 71.1-97.3) and 100% for patients treated without and with rituximab, respectively. Only one of 21 patients treated with rituximab and LMB-based chemotherapy had local early treatment failure but achieved prolonged complete remission with second-line chemotherapy and radiotherapy. Intensive LMBbased chemotherapy with rituximab achieved excellent survival in children/adolescents with PMLBL. Further international prospective studies are required to confirm these results in this population.

Published
2022
Full Text
View/download PDF

19. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses

Author

LIMKIN, Elaine, primary, BLANCHARD, Pierre, additional, LACAS, Benjamin, additional, BOURHIS, Jean, additional, PARMAR, Mahesh, additional, LICITRA, Lisa, additional, LE, Quynh-Thu, additional, YOM, Sue, additional, FORTPIED, Catherine, additional, LANGENDIJK, Johannes, additional, VERMORKEN, Jan B, additional, BERNIER, Jacques, additional, OVERGAARD, Jens, additional, HARRIS, Jonathan, additional, PIGNON, Jean-Pierre, additional, and AUPERIN, Anne, additional

Published
2023
Full Text
View/download PDF

21. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Author

Claire Petit, Anne Lee, Jun Ma, Benjamin Lacas, Wai Tong Ng, Anthony T C Chan, Ruey-Long Hong, Ming-Yuan Chen, Lei Chen, Wen-Fei Li, Pei-Yu Huang, Terence Tan, Roger K C Ngan, Guopei Zhu, Hai-Qiang Mai, Edwin P Hui, George Fountzilas, Li Zhang, Alexandra Carmel, Dora L W Kwong, James Moon, Jean Bourhis, Anne Auperin, Jean-Pierre Pignon, Pierre Blanchard, Anne Aupérin, Ellen Benhamou, Somvilai Chakrabandhu, Anthony TC Chan, Qiu-Yan Chen, Yong Chen, Richard J Chappell, Horace Choi, Daniel TT Chua, Melvien Lee Kiang Chua, Julian Higgins, Ming Huang Hong, Edwin Pun Hui, Chin-Fu Hsiao, Michael Kam, Georgia Angeliki Koliou, Shu-Chuan Lai, Ka On Lam, Michael L LeBlanc, Anne WM Lee, Ho Fun Victor Lee, Wen Fei Li, Yoke Lim, Brigette Ma, Frankie Mo, Roger Ngan, Camille Ollivier, Brian O'Sullivan, Sharon X Poh, Gerta Rücker, Jonathan Sham, Yoke Lim Soong, Ying Sun, Lin-Quan Tang, Yuk Tung, Joseph Wee, Xuang Wu, Tingting Xu, and Yuan Zhang

Subjects
Oncology
Published
2023

23. Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer

Author

Dauzier, Etienne, Lacas, Benjamin, Blanchard, Pierre, Le, Quynh-Thu, Simon, Christian, Wolf, Gregory, Janot, François, Horiuchi, Masatoshi, Tobias, Jeffrey S., Moon, James, Simes, John, Deshmane, Vinay, Mazeron, Jean-Jacques, Mehta, Samir, Zaktonik, Branko, Tamura, Minoru, Moyal, Elizabeth, Licitra, Lisa, Fortpied, Catherine, Haffty, Bruce G., Ghi, Maria Grazia, Gregoire, Vincent, Harris, Jonathan, Bourhis, Jean, Aupérin, Anne, and Pignon, Jean-Pierre

Published
2019
Full Text
View/download PDF

25. The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data

Author

Burdett, Sarah, Rydzewska, Larysa H.M., Tierney, Jayne F., Auperin, Anne, Le Chevalier, Thierry, Le Pechoux, Cécile, Pignon, Jean-Pierre, Arriagada, Rodrigo, Johnson, David H., van Meerbeeck, Jan, Parmar, Mahesh K.B., Stephens, Richard J., Stewart, Lesley A., Bunn, Paul A., Dautzenberg, Bertrand, Gilligan, David, Groen, Harry, Knuuttila, Aija, Vallieres, Eric, Rosell, Rafael, Roth, Jack, Scagliotti, Giorgio, Tsuboi, Masahiro, Waller, David, Westeel, Virginie, Wu, Yi-Long, Yang, Xue-Ning, Navani, Neal, and Fisher, David J.

Published
2019
Full Text
View/download PDF

27. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

Author

Auke Beishuizen, Karin Mellgren, Mara Andrés, Anne Auperin, Chris M Bacon, Simon Bomken, G A Amos Burke, Birgit Burkhardt, Laurence Brugieres, Alan K S Chiang, Christine Damm-Welk, Emanuele d'Amore, Keizo Horibe, Edita Kabickova, Tasneem Khanam, Udo Kontny, Wolfram Klapper, Laurence Lamant, Marie-Cecile Le Deley, Jan Loeffen, Elizabeth Macintyre, Georg Mann, Friederike Meyer-Wentrup, Ulf Michgehl, Veronique Minard-Colin, Lara Mussolin, Ilske Oschlies, Catherine Patte, Marta Pillon, Alfred Reiter, Charlotte Rigaud, Leila Roncery, Itziar Salaverria, Ingrid Simonitsch-Klupp, Anne Uyttebroeck, Jaime Verdu-Amoros, Denise Williams, Wilhelm Woessmann, Andrew Wotherspoon, Grazyna Wrobel, Martin Zimmermann, Andishe Attarbaschi, and Suzanne D Turner

Subjects
Hematology
Abstract

The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) was established 25 years ago with the goal to facilitate clinical trials and research collaborations in the field both within Europe and worldwide. Since its inception, much progress has been made whereby major improvements in outcomes have been achieved. In this Review, we describe the different diagnostic entities of non-Hodgkin lymphoma in children and young adults describing key features of each entity and outlining clinical achievements made in the context of the EICNHL framework. Furthermore, we provide an overview of advances in biopathology with an emphasis on the role of biological studies and how they have shaped available treatments. Finally, for each entity, we describe future goals, upcoming clinical trials, and highlight areas of research that require our focus going forward.

Published
2023

32. Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients

Author

Tao, Yungan, Auperin, Anne, Sire, Christian, Martin, Michel, Saliou, Marie-Gabrielle, Bardet, Etienne, Sun, Xu Shan, Chatellier, Thierry, Morand, Clotilde, Cornely, Alexandre, Angokai, Moussa, Di Rito, Alessia, Kichenin, Ketty, Blanchard, Pierre, D'Onofrio, Ida, and Bourhis, Jean

Published
2017
Full Text
View/download PDF

33. Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis

Author

Petit, Claire, primary, Lee, Anne, additional, Ma, Jun, additional, Lacas, Benjamin, additional, Ng, Wai Tong, additional, Chan, Anthony T C, additional, Hong, Ruey-Long, additional, Chen, Ming-Yuan, additional, Chen, Lei, additional, Li, Wen-Fei, additional, Huang, Pei-Yu, additional, Tan, Terence, additional, Ngan, Roger K C, additional, Zhu, Guopei, additional, Mai, Hai-Qiang, additional, Hui, Edwin P, additional, Fountzilas, George, additional, Zhang, Li, additional, Carmel, Alexandra, additional, Kwong, Dora L W, additional, Moon, James, additional, Bourhis, Jean, additional, Auperin, Anne, additional, Pignon, Jean-Pierre, additional, Blanchard, Pierre, additional, Aupérin, Anne, additional, Benhamou, Ellen, additional, Chakrabandhu, Somvilai, additional, Chan, Anthony TC, additional, Chen, Qiu-Yan, additional, Chen, Yong, additional, Chappell, Richard J, additional, Choi, Horace, additional, Chua, Daniel TT, additional, Chua, Melvien Lee Kiang, additional, Higgins, Julian, additional, Hong, Ming Huang, additional, Hui, Edwin Pun, additional, Hsiao, Chin-Fu, additional, Kam, Michael, additional, Koliou, Georgia Angeliki, additional, Lai, Shu-Chuan, additional, Lam, Ka On, additional, LeBlanc, Michael L, additional, Lee, Anne WM, additional, Lee, Ho Fun Victor, additional, Li, Wen Fei, additional, Lim, Yoke, additional, Ma, Brigette, additional, Mo, Frankie, additional, Ngan, Roger, additional, Ollivier, Camille, additional, O'Sullivan, Brian, additional, Petit, Claire, additional, Poh, Sharon X, additional, Rücker, Gerta, additional, Sham, Jonathan, additional, Soong, Yoke Lim, additional, Sun, Ying, additional, Tang, Lin-Quan, additional, Tung, Yuk, additional, Wee, Joseph, additional, Wu, Xuang, additional, Xu, Tingting, additional, and Zhang, Yuan, additional

Published
2023
Full Text
View/download PDF

35. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials

Author

Tao, Yungan, Aupérin, Anne, Graff, Pierre, Lapeyre, Michel, Grégoire, Vincent, Maingon, Philippe, Geoffrois, Lionel, Verrelle, Pierre, Calais, Gilles, Gery, Bernard, Martin, Laurent, Alfonsi, Marc, Deprez, Patrick, Bardet, Etienne, Pignon, Thierry, Rives, Michel, Sire, Christian, and Bourhis, Jean

Published
2017
Full Text
View/download PDF

39. Improving outcomes of childhood and young adult non-Hodgkin lymphoma (NHL); twenty-five years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL)

Author

Beishuizen A, Mellgren K, Andrés M, Auperin A, Bacon CM, Bomken S, Burke GAA, Burkhardt B, Brugieres L, Chiang AKS, Damm-Welk C, dAmore E, Horibe K, Kabickova E, Khanam T, Kontny U, Klapper W, Lamant L, Le Deley MC, Loeffen J, Macintyre E, Mann G, Meyer-Wentrup F, Michgehl U, Minard-Colin V, Mussolin L, Oschlies I, Patte C, Pillon M, Reiter A, Rigaud C, Roncery L, Salaverria I, Simonitsch-Klupp I, Uyttebroeck A, Verdu Amoros J, Williams D, Woessmann W, Wotherspoon A, Wrobel G, Zimmermann M, Attarbaschi A, Turner SD

Published
2023
Full Text
View/download PDF

40. 243 Sarcomatoid carcinoma in Head and Neck cancers: Clinical features and prognosis.

Author

Loriguet, Léa, Auperin, Anne, Chehab, Randa, Casiraghi, Odile, Moya-Plana, Antoine, Nguyen, France, Tao, Yungan, Bidault, Francois, Garcia, Gabriel, Iacob, Mariana, Fouilloux, Antoine, Ferrand, Francois Régis, Gorzo, Alecsandra, Goada, Dragos, Breuskin, Ingrid, and Even, Caroline

Subjects
*HEAD & neck cancer, *PROGRESSION-free survival, *PROGNOSIS, *SQUAMOUS cell carcinoma, *CARCINOMA, *OVERALL survival
Abstract

Sarcomatoid carcinoma of head and neck is a rare type of squamous cell carcinoma (SCC) with sarcomatoid features associated with a poor prognosis. This study aimed to summarize the clinical characteristics, prognosis and treatment options for these patients. Patients diagnosed with a sarcomatoid carcinoma of the head and neck between December 2012 to November 2022 were selected from the pathology database of Gustave Roussy. The data (patients, tumor characteristics, treatment, outcomes, etc.) were collected retrospectively. Multivariable prognosis analysis of progression free survival (PFS), and overall survival (OS) were performed. A total of 57 cases of sarcomatoid carcinoma were included. There were 41 (72%) males and 16 (28%) females. The median age at diagnosis was 64 years. The oral cavity (32%) and the larynx (26%) were the most common tumor sites, followed by the oropharynx (23%), posterior wall of the pharynx and maxillary sinus (5%). 17 patients (30%) were no smokers. More than half of the patients (65%) presented with advanced-stage disease (T3, T4), 95% of them had no metastatic disease at diagnosis. A total of 37 patients (65%) had no previous history of head and neck cancers (de novo tumors), and 25 (44%) arised in irradiated areas. Among all, 28 (49%) underwent a surgical treatment, for 9 (32%) the resection was R1, 9 patients had perineural invasion, and 6 of them presented vascular embols. 32% had nodal metastasis. The other 51 % of patients received radiochemotherapy (n=15), palliative chemotherapy (n=10), or best supportive care (n=4). The follow-up was 51.8 months. The median [95%CI] OS and PFS were 29.7 months [13.8;49.2] and 9.5 months [7.5;22.8]. The multivariable prognostic analysis showed that age, T stage, site (larynx and oral cavity), no history of head and neck cancer, and the presence of a tumor in irradiated site were significantly correlated with a poor OS. With the exception ofno history of head and neck cancer, all of the above negatively influenced the PFS Sarcomatoid carcinoma is a different entity from the conventional SCC of head and neck. This type of tumor is very aggressive and has a poor prognosis. Tumors in irradiated site have a significant poor prognostic. Further clinical trials are needed to establish the best treatment strategy for these tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. EXCELLENT OUTCOME OF CHILDREN/ADOLESCENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA TREATED WITH LMB-BASED CHEMOTHERAPY WITH RITUXIMAB

Author

Dourthe, M., primary, Phulpin, A., additional, Auperin, A., additional, Couec, M., additional, Dartigues, P., additional, Ducassou, S., additional, Garnier, N., additional, Haouy, S., additional, Leblanc, T., additional, Lambilliotte, A., additional, Leruste, A., additional, Jourdain, A., additional, Spiegel, A., additional, Rigaud, C., additional, Simonin, M., additional, Bonneau, J., additional, Verschuur, A., additional, Plat, G., additional, Poirée, M., additional, Buchbinder, N., additional, Landman-Parker, J., additional, Patte, C., additional, and Minard-Colin, V., additional

Published
2022
Full Text
View/download PDF

43. Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial

Author

G. A. Amos Burke, Marta Pillon, Peggy Dartigues, Gilles Vassal, Anne Uyttebroeck, Alan K. Chiang, Veronique Minard-Colin, Stéphanie Haouy, Rodney R. Miles, C. Patte, Keith Wheatley, Peter C. Adamson, Jozsef Zsiros, Thomas G. Gross, Sarah Alexander, Catherine M. Bollard, Rafael Delgado, Monika Csóka, Donald A. Barkauskas, A. Auperin, and Bernarda Kazanowska

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Vincristine, Cyclophosphamide, business.industry, ORIGINAL REPORTS, medicine.disease, Regimen, Prednisone, Internal medicine, medicine, Rituximab, Doxorubicin, Primary mediastinal B-cell lymphoma, business, Etoposide, medicine.drug
Abstract

PURPOSE A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma (PMLBL) without the use of radiotherapy. No international prospective evaluation of this regimen has previously been reported in children and adolescents. PATIENTS AND METHODS We conducted an international single-arm phase II trial involving patients younger than age 18 years with PMLBL who were to receive six courses of DA-EPOCH-R. The primary end point was event-free survival (EFS). Overall survival and toxicity were also assessed. This trial was registered (ClinicalTrials.gov identifier: NCT01516567 ). RESULTS Analyses were based on 46 patients. The median age was 15.4 years (interquartile range: 14-16 years). The median follow-up was 59.0 months (interquartile range: 52.6-69.2 months). Fourteen events were observed (eight relapses or progressions (including three parenchymal CNS relapses), four residual lymphoma, and two second malignancies). The 4-year EFS was 69.6% (95% CI, 55.2 to 80.9), which did not differ from the rate observed historically ( P = .59). Seven deaths occurred (six disease-related and one second malignancy). The overall survival was 84.8% (95% CI, 71.8 to 92.4). Twenty-two patients (48%) reached dose levels ≥ 4. Nonhematologic adverse events grade ≥ 3 or cardiac adverse events grade ≥ 2 occurred in 47 of 276 (17%) courses and 30 of 46 patients (65%). CONCLUSION DA-EPOCH-R did not improve the EFS compared with a historical control in this first prospective multisite international study of children and adolescents with PMLBL. Further studies are required to determine the optimum therapy for children and adolescents with this lymphoma.

Published
2021

44. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck

Author

F.R. Ferrand, Khalil Saleh, Anne Auperin, Edith Borcoman, Amaury Daste, Christophe Le Tourneau, M. Iacob, Neus Baste, Nicolas Martin, Nadine Khalife, Caroline Even, Esma Saada-Bouzid, Nouritza Torossian, and Joël Guigay

Subjects
Adult, Oncology, Cancer Research, medicine.medical_specialty, Immune checkpoint inhibitors, Young Adult, Internal medicine, medicine, Humans, Adverse effect, Head and neck, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, Squamous Cell Carcinoma of Head and Neck, business.industry, Hazard ratio, Confounding, Age Factors, Retrospective cohort study, Middle Aged, Radiological weapon, business
Abstract

Background Recent meta-analysis showed that immune checkpoint inhibitors (ICIs) have comparable activity between younger and older patients. However, little is known about efficacy and safety of ICI in elderly patients with relapsed/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The aim of this study is to compare the efficacy of ICI for patients aged ≥70 y to that for younger patients, while taking into account potential confounding factors. Methods A retrospective study was conducted at four hospitals in France. Patients treated with ICI for R/M SCCHN between September 2014 and December 2018 were eligible. Patients’ charts were reviewed for clinical and radiological data as well as oncologic outcomes. Results We included 226 patients, of whom 67 were aged ≥70 years. Objective response rate (ORR), median overall survival (OS) and median progression-free survival (PFS) were 23%, 9.7 months and 2.7 months, respectively, for elderly patients, compared to 13%, 8.7 months and 1.9 months for younger patients (respective p-values: 0.071, 0.87 and 0.21). After adjustment for performance status, site of progression, number of ICI drugs, time between initial diagnosis and ICI start and number of previous lines, age ≥70 years was significantly associated with a better PFS (hazard ratio [HR], 0.66; p = 0.021) but not OS (HR, 0.91; p = 0.59). Grade 3-5 adverse events (AEs) occurred in 15% of patients aged ≥70 years and in 8% of younger patients (p = 0.13). Conclusion Patients aged ≥70 years with R/M SCCHN may respond to ICI similarly as younger patients in terms of ORR, OS and PFS, while maintaining comparable rate of AEs.

Published
2021

45. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

Author

Beishuizen, Auke, Mellgren, Karin, Andrés, Mara, Auperin, Anne, Bacon, Chris M, Bomken, Simon, Burke, GA Amos, Burkhardt, Birgit, Brugieres, Laurence, Chiang, Alan KS, Damm-Welk, Christine, d'Amore, Emanuele, Horibe, Keizo, Kabickova, Edita, Khanam, Tasneem, Kontny, Udo, Klapper, Wolfram, Lamant, Laurence, Le Deley, Marie-Cecile, Loeffen, Jan, Macintyre, Elizabeth, Mann, Georg, Meyer-Wentrup, Friederike, Michgehl, Ulf, Minard-Colin, Veronique, Mussolin, Lara, Oschlies, Ilske, Patte, Catherine, Pillon, Marta, Reiter, Alfred, Rigaud, Charlotte, Roncery, Leila, Salaverria, Itziar, Simonitsch-Klupp, Ingrid, Uyttebroeck, Anne, Verdu-Amoros, Jaime, Williams, Denise, Woessmann, Wilhelm, Wotherspoon, Andrew, Wrobel, Grazyna, Zimmermann, Martin, Attarbaschi, Andishe, Turner, Suzanne D, European Intergroup for Childhood Non-Hodgkin Lymphoma, Turner, Suzanne [0000-0002-8439-4507], and Apollo - University of Cambridge Repository

Subjects
Europe, Young Adult, Lymphoma, Non-Hodgkin, Humans, Child
Abstract

The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) was established 25 years ago with the goal to facilitate clinical trials and research collaborations in the field both within Europe and worldwide. Since its inception, much progress has been made whereby major improvements in outcomes have been achieved. In this Review, we describe the different diagnostic entities of non-Hodgkin lymphoma in children and young adults describing key features of each entity and outlining clinical achievements made in the context of the EICNHL framework. Furthermore, we provide an overview of advances in biopathology with an emphasis on the role of biological studies and how they have shaped available treatments. Finally, for each entity, we describe future goals, upcoming clinical trials, and highlight areas of research that require our focus going forward.

Published
2022
Full Text
View/download PDF

46. Impact of COVID-19 on healthcare organisation and cancer outcomes

Author

Caroline Robert, Christophe Massard, Samia Bouhir, Julien Hadoux, Fabrice Barlesi, Emeline Colomba, Isabelle Borget, Stefan Michiels, Julia Bonastre, Charles Honoré, A. Bardet, Matthieu Faron, Anne Auperin, Suzette Delaloge, David Planchard, Lucile Ter-Minassian, Laurence Albiges, Jean-Baptiste Micol, Michel Ducreux, Alderic M. Fraslin, and Jamila Marghadi

Subjects
0301 basic medicine, Cancer Research, medicine.medical_specialty, Survival, Health administration, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Hospital Administration, Neoplasms, Pandemic, Health care, medicine, Humans, Computer Simulation, Pandemics, Diagnostics, Proportional Hazards Models, Original Research, Delay, Hospital resources, SARS-CoV-2, business.industry, Proportional hazards model, Mortality rate, Hazard ratio, COVID-19, Cancer, medicine.disease, Hospitals, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Emergency medicine, business, Delivery of Health Care
Abstract

BACKGROUND: Changes in the management of patients with cancer and delays in treatment delivery during the COVID-19 pandemic may impact the use of hospital resources and cancer mortality. PATIENTS AND METHODS: Patient flows, patient pathways and use of hospital resources during the pandemic were simulated using a discrete event simulation model and patient-level data from a large French comprehensive cancer centre's discharge database, considering two scenarios of delays: massive return of patients from November 2020 (early-return) or March 2021 (late-return). Expected additional cancer deaths at 5 years and mortality rate were estimated using individual hazard ratios based on literature. RESULTS: The number of patients requiring hospital care during the simulation period was 13,000. In both scenarios, 6-8% of patients were estimated to present a delay of >2 months. The overall additional cancer deaths at 5 years were estimated at 88 in early-return and 145 in late-return scenario, with increased additional deaths estimated for sarcomas, gynaecological, liver, head and neck, breast cancer and acute leukaemia. This represents a relative additional cancer mortality rate at 5 years of 4.4 and 6.8% for patients expected in year 2020, 0.5 and 1.3% in 2021 and 0.5 and 0.5% in 2022 for each scenario, respectively. CONCLUSIONS: Pandemic-related diagnostic and treatment delays in patients with cancer are expected to impact patient survival. In the perspective of recurrent pandemics or alternative events requiring an intensive use of limited hospital resources, patients should be informed not to postpone care, and medical resources for patients with cancer should be sanctuarised.

Published
2021

47. 653O Neoadjuvant nivolumab (N) before chemoradiation (CRT) in high-risk HPV driven oropharynx cancer (OPC) - IMMUNEBOOST-HPV: A multicenter randomized phase II trial

Author

Mirghani, H., primary, Even, C., additional, Larive, A., additional, Pere, H., additional, Fayette, J., additional, Geoffrois, L., additional, Clatot, F., additional, Calderon, B., additional, Tao, Y., additional, Nguyen, T.V.F., additional, Fabiano, E., additional, Kreps, S., additional, Veyer, D., additional, Puech, J., additional, Badoual, C., additional, Garic, F., additional, Auperin, A., additional, and Blanchard, P., additional

Published
2022
Full Text
View/download PDF

48. 675P Patterns of radiological responses to anti-PD1 in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in TOPNIVO (T) study

Author

Even, C., primary, Bernard-Tessier, A., additional, Texier, M., additional, Ben Said, O., additional, Iacob, M., additional, Daste, A., additional, Fayette, J., additional, Zanetta, S., additional, Lefebvre, G., additional, Vinches, M., additional, Johnson, A.C., additional, Bozec Le Moal, L., additional, Saada, E.B., additional, Jallut, I., additional, Garic, F., additional, Monard, L., additional, Bourhis, J., additional, Guigay, J., additional, Auperin, A., additional, and Ammari, S., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results